Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, reflecting a minor update to the study record documentation.SummaryDifference0.1%

- Check19 days agoChange DetectedThe revision tag in the page footer was updated from v3.6.0 to v3.6.2, indicating a newer platform release.SummaryDifference0.1%

- Check33 days agoChange DetectedRecruitment status is updated to indicate enrollment is closed. New help pages and navigation tools were added to guide users on reading the study record and joining, with a formatting update to the Intervention/Treatment label.SummaryDifference0.4%

- Check40 days agoChange DetectedRevision label updated to v3.5.5, replacing the previous v3.5.4 in the page history. This indicates a new page revision was published, likely for minor editorial updates.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a small metadata update. This change does not alter the substantive content or data displayed.SummaryDifference0.1%

- Check76 days agoChange DetectedPage revision updated from v3.5.2 to v3.5.3, indicating a new build of the page. The listed change does not alter study content, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.